Transforming Bladder Cancer Treatment with Enfortumab Vedotin and Pembrolizumab

Christof Vulsteke, Head of the Integrated Cancer Center Ghent (IKG) in Belgium, presents new phase III data highlighting a paradigm shift in muscle-invasive bladder cancer using enfortumab vedotin plus pembrolizumab in the perioperative setting. Results show significant improvements in event-free and overall survival, along with unprecedented complete response rates in both cisplatin-eligible and ineligible patients, supporting this combination as a promising new standard of care.